Last updated: February 15, 2026
Overview
NDC 00143-9284 corresponds to Vimizim (elosulfase alfa), a prescription enzyme therapy for the treatment of mucopolysaccharidosis IVA (Morquio A syndrome). It received FDA approval in 2014. Market dynamics, manufacturing costs, payer policies, and competition influence Vimizim pricing and projections.
Market Size and Demand
- Prevalence: Morquio A affects approximately 1 to 3 per 1 million live births globally.
- Estimated Patient Population: US estimates range between 250 and 750 patients. European and other markets collectively increase this estimate to roughly 1,250–2,000 patients.
- Market Penetration: Currently, approximately 70-80% of diagnosed patients receive treatment in developed markets.
Revenue Estimates
- Current Annual Sales: Based on previous reports, Vimizim generated approximately $125 million in 2021. Sales are expected to grow modestly at a CAGR of around 3-5% driven by increased diagnosis and expanded reimbursement.
- Key Growth Drivers:
- Enhanced disease awareness.
- Broader approval in additional countries.
- Early diagnosis leading to early intervention.
Pricing Factors
Price Projections (2023–2030)
| Year |
Projected Price per Patient (USD) |
Notes |
| 2023 |
$375,000 |
Current level, stable for 2023 |
| 2024 |
$370,000–$385,000 |
Anticipated minor adjustments; inflation, reimbursement negotiations |
| 2025 |
$365,000–$385,000 |
Possible stabilization or slight decrease due to biosimilar activities in other markets |
| 2026–2030 |
$360,000–$380,000 |
Marginal variation; patent protections extend until late 2020s, biosimilar competition unlikely before 2030 |
Competitive Landscape
- Biosimilars: No biosimilars for elosulfase alfa currently approved globally. Patent expirations are projected around 2026–2028, with biosimilars possibly entering the market afterward.
- Pipeline Agents: Several gene therapy candidates and alternative enzyme formulations are in clinical trials, potentially impacting long-term demand.
Regulatory and Policy Impact
- Pricing pressures from payers and health authorities may limit price increases.
- Expanded access programs and value-based pricing models could influence actual reimbursement levels.
- Orphan Drug Designation: Offers incentives but does not guarantee price protections.
Market Risks
- Low patient numbers limit revenue growth.
- Entry of biosimilars post-patent expiry could depress prices.
- Variability in global reimbursement policies affects revenue streams.
Key Takeaways
- Average annual price for Vimizim remains around $375,000 per patient.
- Market growth driven by increased diagnosis and approval in new regions.
- Long-term price stability faces pressure from biosimilar development and payer negotiations.
- Revenue growth is limited by the small patient population but sustained by high per-patient prices.
- Competition from emerging therapies, including gene editing approaches, could influence future market dynamics.
FAQs
-
What is the current global market size for enzyme therapies like Vimizim?
Estimated at approximately 1,250–2,000 patients worldwide, limited by disease rarity.
-
When are biosimilars expected to impact Vimizim pricing?
Potentially around 2026–2028, after patent expiry, with actual market entry depending on regulatory approval and market strategies.
-
How does Vimizim's price compare with other enzyme replacement therapies?
It is among the higher-priced enzyme therapies, with wholesale costs near $375,000 annually, compared to similar therapies priced between $250,000 and $365,000.
-
What factors could cause Vimizim’s price to decline?
Biosimilar competition, increased bargaining power of payers, or approval of alternative therapies could lead to price reductions.
-
What are the main revenue drivers for Vimizim sales?
Increased diagnosis, expanded geographic access, and stabilized pricing supported by payer reimbursements.
Sources
[1] FDA Drug Database. Vimizim (elosulfase alfa) label, 2014.
[2] IQVIA. Employer and government drug market data, 2022.
[3] MarketWatch. Lysosomal storage disorder market analysis, 2022.
[4] EvaluatePharma. Biopharma pricing trends, 2022.
[5] U.S. Orphan Drug Act. Policy documentation, 1983.
